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1 SUMMARY 
1.1 Scope of the submission 
• The use of Bortezomib monotherapy for the treatment of multiple myeloma patients 
at first relapse and beyond; this reflects the licensed indication of Bortezomib.  
1.2 Summary of submitted clinical effectiveness evidence 
• One RCT, comparing Bortezomib with high dose dexamethasone in multiple 
myeloma patients who have had a relapse after one to three treatments, was 
included in the manufacturer’s submission.  
• Results of the RCT suggest that Bortezomib increases survival and time to disease 
progression compared with high dose dexamethasone in these patients. 
1.3 Summary of submitted cost effectiveness evidence 
• The cost-effectiveness analysis uses a decision-analytic model (quasi-Markov) to 
estimate the treatment effect with Bortezomib compared with high dose 
dexamethasone.  
• The model uses clinical effectiveness data from the RCT supplemented with data 
from an observational study. 
• Primary analysis presents an estimated cost per-life-year-gained of £30,750. Cost 
per life-year-gained ranges from £27,957 to £36,747 from sensitivity analyses.    
1.4 Commentary on the robustness of submitted evidence  
1.4.1 Strengths 
• Searches for clinical and cost effectiveness studies were adequate and all available 
evidence has been included. 
• The RCT is of reasonable quality when assessed according to NICE internal validity 
criteria.  
• The approach taken to model disease progression and cost effectiveness in this 
patient group seems reasonable. 
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1.4.2 Weaknesses 
• The included RCT is not an absolute reflection of current UK clinical practice so its 
external validity may be questionable. However, the lack of standardisation in the 
clinical management of relapsed myeloma suggests that the impact of this on the 
generalisability of the economic model in terms of patient group and comparator may 
be minimal.  
• The reporting of the trial lacks detail and clarity making interpretation of clinical 
effectiveness results difficult.  
• The manufacturer’s submission does not present quality of life issues in the 
economic model.  Note: The manufacturer has submitted additional information 
presenting analysis on cost per QALY, see Addendum. 
• The sensitivity analyses undertaken in the economic evaluation are limited. 
• Adverse events have not been included in the manufacturer’s model, either in terms 
of loss of quality of life or increased resource use. 
1.4.3 Areas of uncertainty 
• The RCT is poorly reported, making it difficult to assess the overall treatment effect of 
Bortezomib on myeloma. 
• The economic model in the manufacturer’s submission may overestimate the 
treatment effect from the trial for a UK setting. 
• Cost effectiveness results presented may under estimate the cost per life-year-
gained for bortezomib compared to HDD. 
• There may be greater variability in the cost effectiveness of treatment than presented 
in the sensitivity analyses in the manufacturer’s submission. 
1.5 Key issues  
• There is no standard treatment for relapsed multiple myeloma patients which makes 
assessing the effectiveness and cost effectiveness of new treatments problematic in 
terms of the individuality of treatment protocols and which comparators to use.  
• It would be useful for future trials to reflect current practice but this may be difficult as 
this is a quickly developing area where clinicians are eager to have new treatments 
options for patients who do not do not easily fit into stereotypical groups.     
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2 Introduction to ERG Report 
This report is a critique of the manufacturer’s original submission to NICE received on 1 
March 2006. Clarification on some aspects of the submission was requested from the 
manufacturer by the ERG via NICE on 29 March 2006. A response from the manufacturer 
via NICE was received by the ERG on 19 April 2006 and this has been included as an 
Addendum in the ERG report. Annotations referring to the Addendum occur throughout the 
ERG report where applicable. 
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3 BACKGROUND  
3.1 Critique of manufacturer’s description of underlying health 
problem  
The early sections of the manufacturer’s submission report do not include much detail on the 
underlying health problem. The first part of the background chapter focuses on the summary 
of the decision problem, and a critique of this is presented in section 4. Section 21 of the 
manufacturer’s submission (p.14) provides a brief overview of the disease, including 
incidence data and a summary of the disease’s natural history. This appears to be a clear 
and accurate overview of the disease. 
 
3.2 Critique of manufacturer’s overview of current service 
provision  
The manufacturer’s submission correctly states that there is no standard approach to 
treatment at first relapse and that treatment is likely to vary between individuals according to 
clinical condition, age, prior treatment regimen and critically, the timing of relapse in relation 
to previous treatment. A detailed description of possible treatment options at first and 
subsequent relapse is not provided in the manufacturer’s submission.  
 
UK market authorisation is for bortezomib monotherapy only.  However, clinical advisors and 
published guidelines suggest that bortezomib is generally used in conjunction with 
dexamethasone in the UK, which is acknowledged in the manufacturer’s submission; this will 
be for patients with reasonable life expectancy. The manufacturer’s submission mentions 
that the use of bortezomib varies across the UK due to funding constraints as shown in 
Appendix 2 of the manufacturer’s submission. 
 
The manufacturer’s submission justifies the manufacturer’s choice of comparators, but it is 
not clear whether this is representative of UK clinical practice. This is discussed further in 
Section 4.3 below. 
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4 Critique of manufacturer’s definition of decision problem 
4.1 Population 
The study population is defined as multiple myeloma (MM) patients at first relapse and 
beyond. This does not completely match the description of the licence population of ‘patients 
who have received at least one prior therapy (at first relapse) and who have already 
undergone or are unsuitable for bone marrow transplantation’. The population’s 
characteristics are described briefly in section 2 (p. 6) of the manufacturer’s submission.  
This includes median age at diagnosis, one- and five-year survival rates and very limited 
epidemiology regarding sex and ethnic risk factors for this disease (with no supporting data).  
 
Median age at diagnosis in the manufacturer’s submission differs from that found in the 
literature and reported by clinicians. The manufacturer’s submission states that the median 
age at presentation is 65 (p. 6, section 2). Recent clinical publications suggest that the 
average age of UK patients at diagnosis is in the region of 70-72 years. Guidelines on the 
diagnosis and management of multiple myeloma1 indicate that median age at presentation is 
70 years, and elsewhere2 a median age at diagnosis of 68 is quoted. The Cancer Research 
UK websitea cited in the manufacturer’s submission states that ‘more than 80% of cases are 
diagnosed in people over 60 years old’. However, the differences in median ages quoted 
here are probably not clinically significant. 
 
4.2 Intervention 
Bortezomib is a proteasome inhibitor, and works by disrupting normal intra-cellular protein 
regulation, leading to programmed cell death (apoptosis).  
The executive summary states that bortezomib was licensed for the treatment of people with 
relapsed and refractory multiple myeloma in 2004. The marketing authorisation was 
extended in April 2005 to allow use as a monotherapy for the treatment of progressive 
multiple myeloma in patients who had received at least one prior therapy (at first relapse) 
and who have already undergone (or are unsuitable for) bone marrow transplantation. 
 
The description of the intervention in the definition of the decision problem in the 
manufacturer’s submission does not reflect the use of bortezomib in the UK, as mentioned 
                                            
a http://info.cancerresearchuk.org/cancerstats/types/multiplemyeloma/ 
Copyright 2009 Queen's Printer and controller of HMSO. All rights reserved.
                                                                          
 Page 10 of 71 
previously. Therefore there is some concern as to its usefulness in answering a question of 
relevance to the NHS rather than a question relevant to licensing. 
 
4.3 Comparators 
The manufacturer’s submission states that high dose dexamethasone (HDD) is the only 
licensed monotherapy agent with proven efficacy in first relapse patients (p.6), and this is 
therefore used as the comparator in the manufacturer’s submission. HDD, although an 
accepted, active anti-myeloma regimen used in the management of MM in the UK, it is 
usually used for second or subsequent relapse or at first relapse where there are concerns 
about marrow toxicity. Therefore, it appears that the choice of comparator reflects the only 
phase III RCT of bortezomib (the APEX study) rather than possible relevant comparators in 
an NHS context. However, the lack of standardised treatment for patients at first relapse 
means that there is no other obvious comparator, although there are various treatment 
options for this patient group.  
Clinicians and published guidelines suggest that some patients, younger than 65 years, who 
have had a response of >18 to 24 months after a first stem cell transplant at first relapse, 
may be treated with a further regimen leading to a second stem cell transplant. Alkylating 
agents, such as melphalan, with or without corticosteroids, would be regarded as standard, 
non-transplant-directed therapy at first relapse if the period of first response was >12 to 18 
months. Thalidomide, with the addition of dexamethasone if necessary, would also be used, 
especially in early relapse or refractory patients.  As thalidomide is not licensed for use 
within the UK and the optimum dose and duration of therapy is not clear1, it was not 
considered to be a suitable comparator by the manufacturer. 
 
4.4 Outcomes  
The outcomes stated in the manufacturer’s definition of the decision problem are time to 
disease progression, response rates, survival and quality of life. They are appropriate and 
clinically meaningful. No primary outcome is specified. The ERG would have expected 
survival to be the primary outcome measure, although time to disease progression would 
also be valid. 
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5 CLINICAL EFFECTIVENESS 
5.1 Critique of manufacturer’s approach 
5.1.1 Description of manufacturer’s search strategy and comment on whether 
the search strategy was appropriate.  
5.1.1.1 Clinical effectiveness searches 
 
The manufacturer ran searches in the expected core databases of Medline, Medline in 
process, Embase and Cochrane, and checked the websites of ASCO and the American 
Hematology Society for ongoing trials and conference proceedings. The ERG searches 
would have included the ISI Science Citation Index, and conference proceedings databases 
such as ISI Proceedings and Biosis Preview in addition to these. We would also have 
searched the National Research Register, Current Controlled Trials and 
www.clinicaltrials.gov for ongoing trials. 
  
The search question is broken down into population and intervention, as would be expected. 
The population is searched using Medline and Embase descriptors (MeSH and Emtree) and 
free text terms. The search strategy for both of these facets seems sound and reproducible. 
The manufacturer did not give detailed search results (by search line) for all the searches, 
although the results are broken down by database total. The ERG requested further 
information on the numbers of studies identified by each line of the search strategy, and 
these were later provided by the manufacturer (see Addendum).  
 
ERG searches using the NHS-CRD RCT filter identified an additional 109 references in 
Medline, and an additional 143 references in Embase. We also found more results in some 
of the databases when running searches with the manufacturer’s RCT filters. Differences 
could have arisen from the difficulty of translating search terms between databases and the 
use of long nested search strings in the free text searches. The extra references have been 
screened for inclusion/exclusion and do not appear to be relevant references that are 
missing from the manufacturer’s searches.  
 
5.1.1.2 Cost effectiveness searches  
The search strategy for cost effectiveness (economic evaluations) is reproduced in Appendix 
8 (p.127) for all selected databases.  The search strategy is only reported in the context of a 
Copyright 2009 Queen's Printer and controller of HMSO. All rights reserved.
                                                                          
 Page 12 of 71 
review of economic evaluations of bortezomib for MM.  The databases searched are listed 
and seem to be comprehensive. The search was run on the drug intervention alone, which is 
acceptable for identifying specific economic evaluations (but is regarded as too narrow to 
search for other references related to quality of life studies).  
 
The manufacturer’s submission lists additional strategies for economic studies of multiple 
myeloma and survival for people with multiple myeloma in Appendix 10.  There is no 
commentary in the manufacturer’s submission on the search for economic costing studies.  
Section 3.4.1 of the manufacturer’s submission refers to the epidemiology search.  It is not 
clear how these additional searches were used.  The ERG ran two searches for cost 
effectiveness and quality of life in Medline using our standard filters and found approximately 
double the number of papers reported in the manufacturer’s submission.  Again, it is not 
clear whether these additional references would have been relevant to the review.  
 
 
5.1.2 Statement of the inclusion/exclusion criteria used in the study selection 
and comment on whether they were appropriate.  
The manufacturer’s submission reports the results of a systematic review using the following 
inclusion criteria: 
1. study design - RCTs, systematic reviews or meta-analyses; 
2. interventions - bortezomib monotherapy vs. either placebo or another comparator; 
3. population - patients with MM at first relapse, over 12 years old; 
4. outcome measures - no outcome measures are specified in the inclusion/exclusion 
criteria 
 
The inclusion/exclusion criteria seem appropriate and generally reflect the information in the 
decision problem. However, there is some discrepancy between the listed inclusion criteria 
(p. 24) and the table of inclusion criteria (p.25). For example, section 34 ‘inclusion criteria’ 
states ‘clinical studies’ and ‘exclusion criteria’ states ‘non-systematic reviews or editorials’, 
but the text does not discuss whether or not systematic reviews would be included. 
However, the table on p. 25 suggests that systematic reviews and meta-analyses were to 
have been included. This point is relevant because an abstract of a systematic review3 was 
listed as a search result, but was not discussed at all in the manufacturer’s submission. 
 
There is no discussion of whether or not abstracts would be considered for the review, or 
whether this would be restricted to fully published papers. Again, this is relevant because an 
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abstract for a relevant systematic review3 is listed, but no reason given for its exclusion. It 
does not appear in the list of excluded studies in Appendix 10.  
 
Inclusion criteria state that MM patients at first relapse will be included in the review, and that 
trials involving only patients who were at second relapse and beyond will be excluded. The 
manufacturer’s submission does not specify how trials with mixed populations will be 
handled (for example, whether a trial will be included if at least 50% of patients meet the 
inclusion criteria). It is possible therefore that a study which does not strictly reflect the stated 
inclusion criteria could be included in the systematic review. It should also be noted that the 
population defined in the decision problem is MM patients at first relapse and beyond.  
 
Differences exist between the systematic review and trial inclusion/exclusion criteria and 
licence indication of bortezomib. Neither the systematic review nor the trial’s 
inclusion/exclusion criteria mention bone marrow transplantation status, yet the licence 
suggests that bortezomib is only indicated for people who have already undergone or are 
unsuitable for bone marrow transplantation. This may not be an important point as the use of 
bortezomib in the UK would be considered in patients with relapsed myeloma on clinical 
merits irrespective of whether stem cell transplantation had been carried out. The table of 
inclusion criteria states that only studies with more than 20 patients will be included, but 
gives no justification for this. The ERG requested further information from the manufacturer 
on this point, see Addendum for clarification. 
 
No QUOROM flow chart of retrieved studies is presented, and there is some confusion 
around the number of identified studies. Conflicting information was provided on the number 
of references assessed for inclusion. Text in section 32 on p.24 states a total number of 
records for evaluation of 283, indicating that there were 245 from searches, plus extras from 
the Cochrane database and in-house databases. Text in section 35 then states that ‘the 
abstracts of the 257 articles identified were checked for inclusion/exclusion criteria”.  All 
excluded references appear to have been rejected on the basis of their titles and abstracts, 
and no full publications appear to have been retrieved other than the single included RCT. 
The manufacturer’s submission does not state the methods used for screening titles and 
abstracts for inclusion. 
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5.1.3 Identified studies 
Only one RCT was included in the manufacturer’s submission (details are shown in Table 1). 
This has been published as one primary publication4 (referred to as ‘the NEJM paper’ in this 
report) and a series of conferences presentations and abstracts5-10. The manufacturer did 
not include copies of the relevant papers with the submission, and it has not been possible 
to find copies of all the cited abstracts.  
 
Table 1 Identified studies 
Study: Richardson et al. 4 
Methods Participants Outcomes 
Design: RCT 
 
Interventions:   
Group A: bortezomib (1.3mg/ m2 BSA) on days 
1,4, 8 and 11 for 8 21-day cycles, and on days 1, 
8, 15 and 22 for 3 further 35-day cycles, for a 
maximum treatment period of 273 days. 
 
Group B: HDD 40mg on days 1-4, 9-12 and 17-
20 for 4 35-day cycles, followed by treatment on 
days 1-4 for 5 28-day cycles, for a maximum 
treatment duration of 280 days.  
 
Group B  patients were permitted to cross over to 
receive bortezomib in a companion study after 
disease progression 
 
Number of centres: 93 
 
Median duration of treatment:  not stated in 
NEJM paper.  
56% of patients completed 5 3-week cycles of 
bortezomib, and 56% completed 3 5-week cycles 
of HDD. 
29% of bortezomib group completed 8 twice 
weekly cycles, and 36% of the HDD group 
completed 4 cycles.  
9% of bortezomib group and 5% of HDD group 
completed all planned therapy.  
Inclusion criteria: 
measurable progressive 
disease after 1-3 
previous treatments; 
KPS score of ≥ 60; 
platelet count of ≥ 
50,000 per cubic mm; 
haemoglobin level of ≥ 
7.5g per dl; absolute 
Neutrophil count of ≥750 
per cubic ml; creatinine 
clearance of at least 
20ml per min. 
 
Numbers: 669 
participants. 
Group A: 333 
Group B: 336 
 
Median age (10th and 
90th percentiles):  
Group A: 62 (48,74) 
Group B : 61(47,73) 
Primary outcomes: 
Time to disease 
progression 
Secondary outcomes: 
overall and one-year 
survival; response 
rate (complete plus 
partial response); 
duration or response; 
time to 1st evidence of 
a confirmed 
response; time to 1st 
infection of grade 3 or 
higher, and time to 
first skeletal event. 
 
Length of follow-up: 
8.3 months (fully 
published). Updated 
analysis at 22 months 
only available as 
abstract, and contains 
cross-overs. 
BSA= body surface area, KPS = Karnofsky performance scale, 
 
 
Approximately 67% of patients in the APEX study had received ‘prior stem cell 
transplant/high-dose therapy’, but it is not clear from the reporting of the trial how many had 
either received a transplant or were unsuitable for one. Over 50% of included patients had 
received at least 2 prior treatments, and almost 50% of the patients had previous 
thalidomide therapy. ERG requested further information on the timing of previous treatments. 
Further information from the manufacturer suggests that two thirds of patients had received 
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thalidomide therapy in the three months prior to starting bortezomib treatment (see 
Addendum).  
 
The manufacturer’s searches identified an abstract of a relevant systematic review3, but this 
was neither discussed in the text nor specifically excluded from the review.  
 
5.1.4 Details of any relevant studies that were not included in the submission  
The ERG did not identify any relevant studies that were not included in the submission from 
searches undertaken and consultation with experts.  
5.1.4.1 Ongoing studies 
The combination of bortezomib and dexamethasone will be included in a protocol extension 
to the Myeloma IX study following a patient’s first relapse. The study population excludes 
patients who have previously received chemotherapy. This study is planned to close in May 
2008, and has currently recruited 77% of total required participants. 
 
The manufacturer’s submission includes a list of ongoing clinical trials (appendix 3). This 
includes: 
1. a large, multicentre phase III trial (protocol number 26866138MMY3005) comparing the 
efficacy and tolerance of thalidomide + dexamethasone versus thalidomide + 
dexamethasone + bortezomib for MM patients regressing or relapsing after autologous 
transplantation (n=452 patients);  
2. a small phase III trial (protocol number DOXILMMY3001) comparing doxil and 
bortezomib with doxil monotherapy for 20 patients with relapsed multiple myeloma; 
3. a phase III trial protocol (number 26866138MMY001) with a relevant treatment and 
comparator (bortezomib-melphalan-prednisone vs. melphalan-prednisone). However, the 
patient group is newly diagnosed MM patients not suitable for transplant, rather than 
patients at first relapse, so this may not be relevant. 
 
ERG searches on NRR and the FDA website identified a number of records relating to trials 
in appendix 3 and to other, recently completed trials. We did not identify any other relevant 
ongoing trials of bortezomib for patients with multiple myeloma.  
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5.1.4.2 Additional studies 
The manufacturer’s submission also describes two phase II studies (SUMMIT and CREST) 
designed to establish the efficacy of bortezomib and evaluate the safety profile. These trials 
are not included in the systematic review results.  
 
5.1.5 Description and critique of manufacturer’s approach to validity 
assessment 
The manufacturer’s submission authors applied the quality assessment criteria developed by 
NICE, but do not state how many reviewers applied these criteria. The ERG applied the 
same criteria to the included RCT, and agreed with the manufacturer’s submission authors’ 
assessment for all but one criterion (see Table 2). Method of randomisation and 
concealment of allocation are not described fully in the NEJM paper4, and the ERG would 
therefore score it as ‘A’ on the NICE criteria. The manufacturer’s submission authors rate 
randomisation as ‘C’. They cite an interactive voice recognition system that was used for 
randomisation, yet the NEJM paper does not mention this. The manufacturer’s submission 
authors’ assessment must therefore be based on more information than is available in the 
published trial.  
 
The trial was not blinded, but most of the outcome measures were measurable against 
standard criteria so would not have been subject to observer bias. However, some outcomes 
(such as quality of life assessment and reporting of adverse events) could have been 
affected by the lack of blinding. The ERG asked the manufacturer to confirm whether or not 
anyone was blinded in the study, and further information was received as point A8 in the 
Addendum.   
 
Allocation to treatment groups was randomised and stratified by number of lines of prior 
therapy; refractoriness to prior therapy; and baseline serum β2-microglobulin concentration. 
Stratification factors are described in the manufacturer’s submission as being balanced 
between treatment arms, but the number of subjects enrolled in each stratum was not 
controlled. No further data are presented, and it is not possible to check whether adequate 
numbers were represented in each group.  
 
A consort flowchart is presented. However, it does not include enough detail on the patients 
that crossed over from HDD to bortezomib to assess how this may have influenced results.   
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Table 2 ERG quality assessment of RCTs 
Quality criteria Description Score 
Randomisation A) No details of randomisation are available, or the method used was 
inadequate (e.g. randomisation according to the day of the week, 
even/odd medical record numbers).  
B) An insecure randomisation method was used, where clinical staff 
could possibly learn of the treatment assignment (e.g. randomisation 
sequence kept in the clinical area and open/unblinded trial; treatment 
assignment kept in consecutive ‘sealed’ envelopes and 
open/unblinded trial).  
C) A secure randomisation method was used, where the 
randomisation sequence was kept away from the clinical area and 
administered by staff not directly involved in patient care. 
A – no 
details in 
NEJM 
paper4 
Follow-up A) There were significant numbers of drop-outs with no assessment of 
trial outcome(s) in the subjects who dropped out, and drop-out rates 
differed between treated and control groups.  
B) There were some drop-outs with no assessment of trial outcome(s) 
in the subjects who dropped out, and drop-out rates were 
(approximately) equivalent in treated and control groups.  
C) Trial outcome(s) were assessed in all treated and control subjects.  
B 
Blinding of 
outcome 
assessment 
A) There was an inadequate attempt (or no attempt) to blind 
observer(s), and the measurement technique was subject to observer 
bias (e.g. blood pressure measurement with standard 
sphygmomanometer; measurement of vertebral height on an X-ray).  
B) The observer(s) were kept fully blinded to treatment assignment, or 
the measurement technique was not subject to observer bias (e.g. 
measurement of bone mineral density or survival).  
B (TTP 
determined 
by 
computer 
algorithm) 
Other questions: Response 
Was the design parallel-group or cross-
over? Indicate for each cross-over trial 
whether a carry-over effect is likely. 
The trial was parallel group, with HDD patients who 
experienced progressive disease being permitted to 
receive bortezomib at any point during the process in a 
companion study 
Was the trial conducted in the UK (or 
were one or more centres of the 
multinational trial located in the UK)? If 
not, where was the trial conducted and is 
clinical practice likely to differ from UK 
practice? 
Trial was conducted at 93 centres in US, Canada, Europe 
and Israel. NEJM paper gives no information on UK 
centres. Manufacturer’s submission states that 7 UK 
centres were involved, with a total of 51/669 patients.  
How do the subjects included in the trial 
compare with patients who are likely to 
receive the drug in the UK? Consider 
factors known to affect outcomes in the 
main indication such as demographics, 
epidemiology, disease severity, setting.  
Trial participants may have been younger than those in 
the UK, but otherwise appear comparable.  
For pharmaceuticals, what dosage 
regimens were used in the trial? Are they 
within those detailed in the Summary of 
Product Characteristics? 
bortezomib (1.3mg/ m2 BSA) on days 1,4, 8 and 11 for 8 
21-day cycles, and on days 1, 8, 15 and 22 for 3 further 
35-day cycles, for a maximum treatment period of 273 
days. 
40mg HDD on days 1-4, 9-12 and 17-20 for 4 35-day 
cycles, followed by treatment on days 1-4 for 5 28-day 
cycles, for a max treatment duration of 280 days.  
Dosage regimens are as specified in SPC. 
What was the median (and range) 
duration of follow-up in the trial? 
Not stated in NEJM paper. Manufacturer’s submission 
states median 21.9 months (ref 9-abstract), range 0-35.6 
months 
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5.1.6 Description and critique of manufacturer’s outcome selection 
The manufacturer’s submission did not specify any outcome measures that would be used 
as part of the inclusion criteria for the selection of studies. ERG would have expected 
outcomes such as survival and time to disease progression to be inclusion criteria. 
 
5.1.7 Description and critique the statistical approach used 
The ITT population was defined as all patients who were randomised to treatment (n=669), 
and the manufacturer’s submission states that patients in this population were analysed 
according to the treatment to which they were randomised. Safety analyses were based on 
patients who received at least one dose of the study drug, but according to the treatment 
they actually received.  
 
Interim results at 8.3 months are presented as ITT for all 669 patients. The manufacturer’s 
submission authors describe the interim analysis as being based on the methods of O’Brien 
and Fleming (manufacturer’s submission ref 33). It was planned to take place when half of 
the total required number of events had occurred (231 patients with progressive disease), 
and was anticipated to take place 18.5 months after the first patient was enrolled. Interim 
analysis took place at only 8.3 months, after a statistically significant difference in time to 
disease progression was identified.   
 
There is some confusion surrounding timing of cross-overs in the trial. The NEJM paper4 
states that patients were allowed to cross-over after interim analysis (median time 8.3 
months), and this is also suggested by the flow chart on page 35. However, the 
manufacturer’s submission (p.46) states that “The design of APEX allowed for any HDD 
patient experiencing disease progression to be offered bortezomib therapy. At interim 
analysis (median follow-up 8.3 months), 44% of HDD patients had crossed over to receive 
bortezomib.”  The ERG requested further information from the manufacturer regarding the 
timing of cross-overs, and the number of patients receiving which treatment during the 
earlier stages of the trial. The manufacturer’s response suggests that cross-overs took place 
before the interim analysis – see Addendum point A1.  
 
The manufacturer’s submission states that: “A total of 60 (9%) of the 669 patients 
randomised into the study were found to be refractory to dexamethasone, including 32 (10%) 
of 333 bortezomib patients and 28 (8%) of 336 HHD patients.”  (p.56). There doesn’t seem 
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to be any mention of how this would have affected power calculations. The NEJM paper4 
states that post-hoc analysis without these patients still found significant benefits for 
bortezomib. However, the text on the power calculation states that: “a sample size of 310 
patients per treatment group provided 80% power to detect a 30% difference in the time to 
disease progression between the two groups.” Therefore, removing the refractory patients 
would bring the group size to a level (slightly) below that required for statistical power. The 
ERG requested further information from the manufacturer regarding the effect on power 
calculations of removing these patients from time to progression (TTP) analyses. The 
manufacturer confirmed that statistical power was maintained, as the time to disease 
progression was so much higher than predicted (>70% compared with the required 30% 
difference). See Addendum for further details.  
 
Quality of life data were assessed using a modified intention to treat analysis. The ERG 
requested further information on the statistical methods used for this. The manufacturer 
confirmed that the modified ITT was only used for this outcome measure, and that 44 
patients were excluded from the analysis (see Addendum). .  
 
Hazard ratios were presented for key outcome measures, but it was not possible to check 
these as insufficient data were reported. For example, in Table 10 (p.49), HDD results are 
reported as ‘non evaluable’, yet a hazard ratio and p value for treatment difference are 
reported.  
 
Due to the early termination of the APEX trial a high level of censoring was applied to TPP 
and survival data, and it is not clear what impact this as well as the high rate of attrition will 
have had on outcomes. Also, it is not known how the high rate of crossovers from HDD to 
Bortezomib affected results; it may be that the effect of crossovers was to reduce the 
difference in effectiveness between the two groups but lack of clarity regarding statistical 
analysis hinders this conclusion.   
 
5.1.8 Summary statement of manufacturer’s approach  
• The manufacturer’s submission appears complete with regard to relevant studies, with 
one RCT meeting the inclusion criteria.   
• Quality assessment of the included study according to the NICE criteria seems to be 
adequate although details of the process, in terms of whether it was performed by two 
independent reviewers, are missing. 
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• The submitted evidence generally reflects the decision problem defined in the 
submission, although there appear to be some small inconsistencies which probably 
relate more to reporting than actual differences.  
• There is uncertainty about the statistical methods used in the analysis because of lack of 
clarity in terms of patient numbers and the intervention they received at any time 
(crossovers, drop-outs, length of follow-up) and because point estimates and confidence 
intervals are not presented consistently for all outcomes.    
 
5.2 Summary of submitted evidence  
5.2.1 Summary of results 
Clinical evidence reported in the manufacturer’s submission is based on results from the 
APEX trial which is published as one full publication4 (NEJM) and a series of abstracts. 
Clinical effectiveness results are not fully tabulated in the manufacturer’s submission for 
each outcome and time point, and there are a number of differences between the 
manufacturer’s submission and the NEJM paper in reporting of results.    
 
There are differences in the reporting of baseline characteristics, such as the number of 
patients receiving more than one prior therapy. The percentages of patients receiving 2, 3 or 
4 lines of previous therapy in the manufacturer’s submission are 98%, 82%, and 34% for the 
bortezomib group, and 99%, 84% and 35% for the HDD group.  However, in the NEJM 
paper4, 56% of bortezomib patients and 58% of HDD patients had received 2 or 3 therapies, 
and 4% of bortezomib patients and 7% of HDD patients had received 4 or more previous 
therapies. 
 
There are other small differences between the baseline characteristics in the NEJM paper4 
and in the manufacturer’s submission (Table 7, p.33). Karnofsky Performance Scale (KPS) 
scores  ≥ 70 are reported in the NEJM paper, whereas KPS scores ≥ 60 and ≥ 80 are 
reported in the manufacturer’s submission. However, the manufacturer’s submission’s KPS 
≥ 60 figures are the same as the NEJM KPS ≥ 70 ones. It is not clear where the 
manufacturer’s submission’s KPS ≥ 80 figures come from as these aren’t in the NEJM 
paper. These figures are not reported for the whole ITT population, and use n=322 and 
n=325 for bortezomib and HDD, respectively. Serum β2-microglobulin levels are reported as 
medians in the NEJM paper, but the manufacturer’s submission presents these as β2M>2.5 
and β2M>5.5. It is not clear where this data comes from. CrCI ≤ 20 is presented in the NEJM 
paper whereas CrCI ≤ 60 is shown in the manufacturer’s submission. These figures are quite 
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different (8/330 and 5/323 in the NEJM paper, 110 and 111 in the manufacturer’s 
submission). 
 
A table of baseline values is presented, but no P values are shown. The two groups are 
described as: “…comparable with regards to several baseline disease characteristics, 
including amount of serum and urine M-protein present, proportion of patients with abnormal 
skeletal survey findings and with plasmacytomas, serum calcium, C-reactive protein and β2-
microglobulin levels, renal function, and refractoriness to prior therapy” (p.33). However, 
abnormal skeletal survey, plasmacytomas, hypercalcaemia and corrected serum Ca are 
shown in the manufacturer’s submission, but are not in the NEJM paper4, so it is not clear 
where some of this information comes from.  
 
The primary outcome measure is time to disease progression (TTP). This is defined as the 
duration from the date of randomisation until the date of first documented evidence of 
progressive disease (such as raised M-proteins or new skeletal event) or relapse for patients 
who experienced a complete response.  Evidence of progressive disease included elevation 
of M-proteins, skeletal events, and other measurable indicators which could be considered to 
be free from any observation bias. The manufacturer’s submission authors state that TTP 
was chosen as the primary outcome “due to its accepted correlation with survival and 
because of its clinical relevance”.  Given the high mortality rate for this condition, the ERG 
wondered whether survival would have been a more appropriate primary outcome and 
requested further information from the manufacturer on this point. However, clinical advisors 
indicate that TTP is an appropriate primary outcome. Response from the manufacturer’s 
justifying their choice of TTP as the primary outcome is included in the Addendum.  
 
Response rates (overall, time to achieving and duration of), survival (overall and one year) 
and quality of life are secondary outcome measures.  Response rates were based on the 
European Group for Blood and Marrow Transplant criteria, and were determined by a 
computer algorithm developed by the sponsor and validated by the Independent Review 
Committee. Assessment of this outcome measure should therefore have been free from 
bias, despite the unblinded nature of the trial. ERG requested further information on the 
members of the independent review committee, and this was later provided by the 
manufacturer (see Addendum).  
 
Time to new skeletal event (e.g. new fractures, irradiation of or surgery on bone, or spinal 
cord compression) is listed as an outcome measure but the results are not discussed in 
detail in the manufacturer’s submission. In this population, new skeletal events would not be 
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a sufficient objective criterion as the extent and nature of the disease would vary according 
to the individual myeloma patient and to the time frame of the disease. Previous skeletal 
disease/events would be a pre-existing risk factor for subsequent events.    
 
The incidence of adverse events is listed in the manufacturer’s submission. The unblinded 
nature of the trial may have affected the reporting of these. Grade 3 infections are discussed 
as a separate measure, assessed using the National Cancer Institute Common Toxicity 
Criteria.  
 
Quality of life outcome measures used were the EORTC QLC-C30 questionnaire, and a 
neuropathy-specific measure (FACT/GOG-Ntx). Data are not presented in the 
manufacturer’s submission. The ERG requested more information on this outcome from the 
manufacturer, and the manufacturer supplied a conference presentation with further data.  
 
The NEJM paper4 discusses key results in the text, but does not tabulate the main outcome 
measures. These are presented as a series of small graphs, and it is not possible to read 
accurate data from these. The information in Table 3 is taken from the text of the NEJM, with 
additional information from the manufacturer’s submission which could not be verified shown 
in italics.  
 
Table 3 Summary of interim results (8.3 months) and one year survival from NEJM publication4 
Outcome measure Bortezomib (n=333) HDD (n=336) 
TTP 
Median TTP (95% CI) 
Hazard ratio (95% CI) 
P value 
Increase of 78% a 
6.2 months (4.6, 6.9) 
0.55 (0.44, 0.69) 
p<0.001  
3.5 months (2,8, 4.2) 
Overall survival b median 
Months (95% CI) 
Hazard ratio (95% CI) 
P value 
16.6 (16.6, NE c) 
 
0.57 (0.40, 0.81) 
p=0.001(p=0.0013 in  
manufacturer’s submission)  
Actual  figures not reported 
One year survival b 
P value 
80% 
p=0.003  
66% 
 Bortezomib (n=315), not ITT HDD (n=312), not ITT 
Overall response rate, n(%) 
Complete response, n(%) 
Near complete response, n(%) 
Partial response (excluding near  
complete response), n(%) 
Median time to response 
Median duration of response 
121(38) p<0.001 
20(6) p<0.001 
21(7) p<0.001 
80(25) p<0.001 
 
43 days 
8 months 
56(18) 
2(<1) 
3(<1) 
51(16) 
 
43 days 
5.6 months 
a stated to be 58% on p.45 of the manufacturer’s submission and 78% elsewhere in the report and in the 
NEJM publication4 
b includes 44% of HDD patients who crossed over to companion study after experiencing progressive disease 
on HDD prior to the interim analysis. 
c NE was not defined in the manufacturer’s submission report. ERG requested clarification of this, and it was 
confirmed to mean ‘not evaluable’ 
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There is very little discussion of the primary outcome measure (TTP) in the manufacturer’s 
submission report, and the majority of the results section is based on analysis of response 
rates.  A significant increase in TTP (primary outcome) is reported for the bortezomib arm, 
but this is stated to be 58% in one part of the manufacturer’s submission (p. 45) and 78% 
elsewhere in the report (p.47). The latter figure corresponds to results in the NEJM.  ERG 
requested clarification of this point from the manufacturer, who confirmed that the figure 78% 
was correct. 
 
Overall survival was stated to be significantly prolonged for patients in the bortezomib 
treatment group compared to patients in the HDD group, with a hazard ratio of 0.57 
(p=0.0013) (p.47). It is not clear where this information comes from. The NEJM paper states 
that, at interim analysis, bortezomib patients had a significantly improved overall survival 
(p=0.04) compared with HDD patients, but does not give any further information other than 
in graphs which are too small to read accurately.  
 
Both the NEJM paper and the manufacturer’s submission (p.47) state that one-year survival 
was significantly prolonged in the bortezomib arm, compared to the HDD arm (p=0.003). The 
manufacturer’s submission states that patients in the bortezomib group experienced a 41% 
decreased risk of death in the first year of treatment (HR 0.57, p=0.001). This analysis of 
overall survival includes data from 147 patients in the HD group who had disease 
progression and subsequently crossed over to receive bortezomib in a companion study 
(44%). 
 
Statements in the manufacturer’s submission regarding response to therapy (n=627, not 
ITT) reflect data in the NEJM paper (and in abstracts for later results) although no 
information was found in the NEJM paper4 regarding durability of responses.  
 
5.2.1.1 Updated analyses 
Updated analyses in the manufacturer’s submission generally reflect data in published 
abstracts, but confidence intervals included in the manufacturer’s submission are from extra 
information not available in these. The 22 month data shown in the manufacturer’s 
submission’s Table 10 are referenced as coming from reference 9, but do not seem to be in 
this abstract. The partial response rate at 15.8 months in table 11 of the manufacturer’s 
submission is 87 (28%), whereas the figures are higher in the cited abstract (manufacturer’s 
submission ref 9) at 108 (34%).  Table 12 in the manufacturer’s submission shows 
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percentage of responders by treatment cycle. The data for this come from ‘Data on file, 
Ortho Biotech’ so we cannot check this.  
 
5.2.1.2 Health related QoL  
The manufacturer’s submission text reflects information in the cited reference. Table 14 data 
is not from the referenced abstract, so cannot be cross-checked. 
 
5.2.1.3 Subgroup analyses 
Subgroup analyses of ‘earlier vs. later bortezomib’ are presented on p.54 of the 
manufacturer’s submission, and these data generally reflect data in the cited abstract. No 
supporting data were found in the cited abstract for extended overall and one year survival. 
Information in Appendix 5 of the manufacturer’s submission discusses survival in relation to 
number of previous therapies, which relates to earlier versus later treatment with bortezomib.  
 
Subgroup analyses of high-risk patients reflect data in the cited reference. It is not clear 
where the data for low risk patients come from, and no supporting data were found for the 
stated 47% higher risk of death for the HDD arm for patients <65 yrs old (p.56).  
 
5.2.1.4 Adverse events 
All adverse events in the NEJM paper are presented in the manufacturer’s submission. 
Clinical advisors consulted by the ERG confirmed that the adverse events observed in the 
trial were to be expected in the patient group, and that they were manageable and had 
relatively mild effects. 
 
P values are not presented for adverse events, and there are some large differences 
between the groups (e.g. 57% vs. 21% for diarrhoea, 57% vs. 14% for nausea, peripheral 
neuropathy 36% vs. 9%, thrombocytopenia 35% vs. 11 % for bortezomib and HDD 
respectively). P values are not presented for differences in withdrawals due to adverse 
events, and these seem quite high in the bortezomib group (37% vs. 29%). 
 
Grade 3 adverse events were reported in 61% of patients receiving bortezomib and in 44% 
of patients receiving dexamethasone. Both the manufacturer’s submission and the NEJM 
state this, but the manufacturer’s submission does not include the significant p values stated 
in the NEJM paper (p<0.01). The manufacturer’s submission discusses the rate of grade 3 
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infections rather than grade 3 events, stating that this is 13% in the bortezomib group and 
16% in the HDD group (p=0.19). The NEJM paper is referenced for this information, but 
does not seem to contain these data.  The ERG requested further information from the 
manufacturer on this point- see Addendum for details. 
 
5.2.2 Critique of submitted evidence syntheses 
No evidence synthesis in the form of a meta-analysis was possible as there was only one 
RCT, and this was reported by narrative means. 
 
5.2.3 Summary 
• The manufacturer’s submission probably contains an unbiased estimate of the treatment 
effect of bortezomib within the stated scope of the decision problem. This is based on the 
results of a single RCT which is of reasonable quality when judged using the NICE 
quality assessment criteria, but the reporting of the trial results is not totally transparent 
and not all results are fully tabulated for each outcome. It is difficult to interpret the data 
with full confidence due to the lack of details and unclear reporting of cross-overs from 
the HDD group to the bortezomib group, censoring of data and the reporting of relative 
rather than absolute values for some outcomes, and the discrepancies between the 
manufacturer’s submission and the paper published in the NEJM. Whilst these factors 
make it difficult to assess the size of the treatment effect, these limitations probably do 
not significantly affect the overall results especially in the light of clarifications received 
from the manufacturer.     
• Results suggest that bortezomib treatment in MM patients who have had a relapse after 
one to three treatments is superior to HDD in terms of survival, time to disease 
progression and response rates.    
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6 ECONOMIC EVALUATION 
6.1 Overview of manufacturer’s economic evaluation 
The manufacturer submission (received 1st March 2006) to NICE includes (i) a short report 
on the cost effectiveness literature available to inform on economic evaluations of 
bortezomib in patients with MM (4 references, 2 of which are conference abstracts, Table 22 
p71), (ii) reference to an early economic analysis undertaken using individual patient-level 
trial data (from Phase II RCT), and (iii) a report on an economic evaluation undertaken and 
presented specifically for the NICE STA process.   
Note:  See Addendum to this report, where the manufacturer reports additional information in 
response to some specific early questions from the ERG. 
 
The results from the economic evaluation are presented for the base case assumptions (i.e. 
patients with 1 relapse, up to 6 treatment regimens), and thereafter for a further three 
scenarios; (1) limiting the number of cycles of bortezomib in non-responding patients, (2) 
using the overall population of the APEX trial (i.e. not limited to 1 relapse), (3) looking at 
treatment using bortezomib and HDD in combination versus HDD only. 
 
CEA Methods 
The CEA uses a decision-analytic model (quasi-Markov) to estimate the effect of treatment 
with bortezomib compared to HDD, summarised below:   
 
6.1.1 Natural history 
The model uses (non-trial) observational data to predict the treatment experience of a cohort 
of patients treated with HDD.  The patient group are defined as MM patients who have 
experienced a first relapse of MM treatment.  Data from the RCT on HDD are deemed to be 
unavailable/inappropriate because of the early termination of the trial and subsequent 
inability to predict long term outcomes and mortality data with HDD.  The model uses data 
from the Mayo Observational Study11 (Kumar et al 2004) to model this baseline/comparator 
cohort.  Data from the Mayo Study are from patients who have been treated with a range of 
different drugs, although few of these were treated with HDD. The submission states that 
188 patients (32.5%) were treated at some point in their follow-up with VAD (combination of 
vincristine, adriamycin and dexamethasone), with 74 of these receiving VAD after their first 
relapse. The model predicts treatment experience, rather than disease progression, 
modelling the flow of patients through a series of treatment regimens (from regimen 2 to 6).  
There are two general health states used in the model; these are ‘on treatment regimen i’, 
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and ‘death whilst on treatment regimen i’ (i=1 to 6).  These health states apply to each of the 
potential treatment regimens (regimens 2 to 6), therefore there are 10 health states in which 
patients can arrive (5 regimens x 2 states). In any cycle patients may remain on that 
treatment regimen, progress to a new regimen or die on that regimen. The first and second 
cycle times are 3-months each, the third cycle time is 6 months, and all subsequent cycles 
are 1-year.  There are 18 time cycles in the model, with all patients starting in the second 
regimen, giving the model a time horizon of 15-years (a lifetime horizon in this patient 
group). 
 
6.1.2 Treatment effectiveness 
The clinical effectiveness data from the APEX RCT, showing a relative benefit in time to 
treatment progression (HR=0.56) and a relative benefit in overall survival (HR=0.42), are 
applied to the baseline prediction for HDD patients.  The model adjusts the baseline 
transition rates (between health states) according to the hazard rates estimated in the APEX 
RCT (bortezomib vs. HDD). The model uses the comparative data to simulate the treatment 
effect from bortezomib, its impact on survival, and the subsequent cost effectiveness of 
treatment.  Treatment effect on adverse events is not included in the CEA.  Bortezomib is 
assumed to have a treatment effect lasting for up to three years. 
 
6.1.3 Health related quality-of-life 
The manufacturer’s submission presents results from CEA as cost per life-year-gained; it 
does not use a single index measure of HRQL to calculate QALYs.  The submission 
presents some discussion to justify this approach.  The justification is based on the 
manufacturer’s opinion that “increased survival is the single most important outcome for 
clinicians and patients” (p76), that meaningful interpretation of data collected on EQ-5D 
within the APEX trial was not possible, and a stated view from the manufacturer that there is 
uncertainty over the validity of the EQ-5D in MM patients.  On this latter point the submission 
includes an outline of views from a seven person focus group (MM patients), which reports 
that the main finding was “the EQ-5D is unlikely to be an appropriate utility measure in this 
patient group” (p77). Whilst the submission does highlight, from focus group findings, that 
MM would be expected to have a considerable impact on health related utility, the analysis 
uses survival (life years gained) only, with no consideration of HRQL. 
Note:  See Addendum to this ERG Report, where the manufacturer provides additional 
information including estimates of cost per quality-adjusted life-year (QALY). 
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6.1.4 Resources and costs  
The dose data for bortezomib is from the APEX RCT, and other resource use data are from 
a published study12 (Bruce et al 1999) reporting on a survey of clinicians (expert opinion) 
with experience of treating patients in the MRC VI myelomatosis trial13 (Table 26,27 p80,81).   
6.1.5 Discounting 
A discount rate of 3.5% is used for future costs and life years. 
 
6.1.6 Sensitivity analyses 
Sensitivity analysis is reported: simple one-way sensitivity analyses, probabilistic sensitivity 
analyses, and scenario analyses. 
 
6.1.7 Model validation 
The submission reports model validation for survival against the Mayo clinic observation arm 
for the HDD baseline cohort (submission, Appendix 12). Survival is then calibrated to the 
control arm of the APEX trial (submission, Appendix 12). 
 
6.2 Results 
Results are presented as cost per life-year-gained, with incremental costs and life-years-
gained also presented separately (in most cases).  The primary analysis presents an 
estimated cost per life-year-gained of £30,750.  One-way sensitivity analysis is reported for 
the variables of time to progression (hazard rate), overall survival (hazard rate), duration of 
treatment effect, treatment cost, and other cost.  A limited range of analyses is reported, with 
the cost per life-year-gained ranging from £27,957 to £36,747 in these analyses. Table 4 
below summarises the results presented in the submission for the primary analysis 
(deterministic methods), probabilistic analyses (range) and for the scenario analyses 
undertaken. 
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Table 4 Cost effectiveness results presented in manufacturer’s analyses 
Analysis Difference in mean 
discounted overall 
survival (months) 
Difference in mean total 
costs 
Estimated cost per 
discounted life-year-
gained 
Primary analysis 
(patients with  1 relapse) 9.9 £25,327 £30,750 
Primary analysis with 
probabilistic sensitivity 
analysis   
£26,855  
(5th percentile) 
£38,564  
(95th percentile) 
Scenario: only 3 cycles 
for non-responders 8.2 £19,172 £27,926 
Scenario: overall Apex 
data (i.e. patients with 1 
or more relapse) 
7.3 £24,165 £39,954 
Scenario:  bortezomib + 
HDD versus HDD alone 11.0 £25,898 £28,281 
Note:  See Addendum to this ERG Report, where the manufacturer provides additional 
information, including cost per QALY estimates. 
 
6.3 Critical appraisal of the manufacturer’s submitted economic 
evaluation 
6.3.1 Critical appraisal of economic evaluation methods 
The ERG have considered the methods applied in the economic evaluation in the context of 
the critical appraisal questions listed in Table 5 below, drawn from common checklists for 
economic evaluation methods (e.g. Drummond et al 1997).14 
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Table 5 Critical appraisal checklist of economic evaluation 
Item 
Critical 
Apprai
sal 
Reviewer Comment 
Is there a well defined question? ? - Yes None 
Is there a clear description of 
alternatives? 
? - Yes Bortezomib versus HDD (primary analysis) 
Has the correct patient group / 
population of interest been clearly 
stated? 
? – 
Yes/No 
The CEA uses MM patients after 1st relapse for the primary 
analysis.  This is a subgroup of the eligible patient group 
from the licence indication.  Scenario analysis presents 
results using the overall trial group (eligible group) of 
patients with at least one relapse. 
Is the correct comparator used? ? Whilst the analysis justifies the use of HDD as the 
comparator, clinical opinion suggests that HDD is not a 
commonly used comparator strategy in the UK.  Although 
HDD is one of a variety of approaches that can be used for 
treating MM at 1st relapse. The manufacturer’s submission 
justifies the used of HDD as the comparator on the grounds 
that there is no UK consensus on best practice for the 
treatment of MM at first relapse and that HDD is commonly 
used. Furthermore they comment that thalidomide is not an 
appropriate comparator.  
Is the study type reasonable? ? - Yes CEA model used.  But no CUA results presented. 
Is the perspective of the analysis 
clearly stated? 
? - Yes Perspective stated as UK NHS 
Is the perspective employed 
appropriate? 
Cost: ? 
- Yes 
Outcom
es: ?/? 
Submission appears to adopt a UK NHS and PSS 
perspective for costs (consistent with NICE reference case).  
Perspective on outcomes is that of the patient, but not all 
effects considered (i.e. HRQL not considered) 
Is effectiveness of the intervention 
established? 
? The CEA is based on clinical effectiveness data from the 
APEX RCT.  Hazard rates calculated as part of the APEX 
analysis are applied in the CEA.  Detail is presented on the 
RCT, but interpretation of trial findings, and consideration of 
methods employed are required by NICE. 
Has a lifetime horizon been used 
for analysis (has a shorter horizon 
been justified)? 
? - Yes CEA uses 15-year time horizon, which is lifetime in this 
patient group. 
Are the costs and consequences 
consistent with the perspective 
employed? * 
? – 
Yes/No 
Costs appear to be consistent with perspective employed, 
but limited info/justification provided. 
Consequences limited to patient life-years-gained. 
Is differential timing considered? ? - Yes None 
Is incremental analysis 
performed? 
? - Yes None 
Is sensitivity analysis undertaken 
and presented clearly?   
? – 
Yes/No 
Yes sensitivity analysis is undertaken, but it may be 
regarded as limited. 
* More on data inputs for costs and consequences in the review of modelling methods below 
 
Note:  See Addendum to this ERG Report, where the manufacturer provides additional 
information, including cost per QALY estimates. 
 
 
6.3.2 NICE reference case 
Table 6 reports the manufacturer’s submission against the requirements of the NICE 
reference case.  There is some overlap with the items presented above on the general 
approach for the economic evaluation.  There is some interpretation required of the 
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comparator used in the analysis (HDD) in the context of routine practice in the UK.  The fact 
that the submission does not include consideration of HRQL, and the subsequent 
presentation of cost per QALY, is highlighted heavily in the cross referencing of the 
submission with the NICE requirements for technology appraisals. 
 
Table 6 NICE reference case requirements 
NICE reference case requirements (see detail in NICE report): 
 
Included in 
Submission 
Decision problem: As per the scope developed by NICE Comparator: 
Alternative therapies routinely used in the UK NHS 
Perspective on costs: NHS and PSS 
Perspective on outcomes: All health effects on individuals 
Type of economic evaluation: Cost effectiveness analysis 
Synthesis of evidence on outcomes: Based on a systematic review 
Measure of health benefits: QALYs 
Description of health states for QALY calculations: Use of a standardised and 
validated generic instrument 
Method of preference elicitation for health state values: Choice based method 
(e.g. TTO, SG, not rating scale) 
Source of preference data:  Representative sample of the public 
Discount rate: 3.5% pa for costs and health effects 
 
N/A 
? 
? 
X 
? 
X 
X 
X 
 
X 
 
X 
? 
 
N/A=not applicable 
 
Note:  See Addendum to this ERG Report, where the manufacturer provides additional 
information, including cost per QALY estimates. 
 
6.3.3 Modelling methods 
An outline critical review of modelling methods has been undertaken.  The review has used 
the framework for good practice in modelling presented by Philips et al (2004)15  as a guide, 
addressing issues of model structure, structural assumptions, data inputs, consistency, and 
assessment of uncertainty. 
 
6.3.3.1 Modelling approach / Model Structure 
The manufacturer’s submission provides very little commentary on the development of the 
model structure, other than stating that clinical experts were involved in all stages of the 
modelling approach.  The model structure covers the treatment of MM, rather than 
presenting a framework depicting the natural history of disease for MM (e.g. by type of 
response, remission, plateau, for disease progression).  Therefore the health states used 
predict the progress of patients to different treatment regimens and to death, rather than the 
underlying biological process of the disease.  Competing theories of model structure have 
not been discussed in the report. 
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The model is described as a semi-Markov approach, and whilst noting the points above, it 
would appear to be an appropriate modelling approach given the decision problem, the data 
available, and the specified causal relationships (e.g. impact of relapse on overall survival) 
within the model. 
 
The cycle length used in the model is variable, with the first two cycles at 3-months and the 
third at 6-months, with a 1-year cycle length used thereafter.  This approach fits the model 
around the trial data available, in the first 12 months, and applies a 1-year cycle thereafter.  
Given that the time to relapse (between different regimens) may be an important factor in the 
prognosis of disease a 1-year cycle may not be appropriate, and the use of a 3-month or 6-
month cycle throughout the time horizon may reflect a better profile of disease over time. A 
half-cycle correction has not been used.  
 
The time horizon of the model is 15-years, and reflects a lifetime horizon (in patients with 
MM at mean age of 65-years).  Mortality in the patient group is high and a shorter time 
horizon may be justified.  No sensitivity analysis is reported against the issue of time horizon. 
 
Sources of data used to develop/populate the model structure are specified (e.g. APEX RCT 
data, observational data from the Mayo clinic). 
 
6.3.3.2 Structural Assumptions 
The submitted economic evaluation assumes that modelling ‘treatment’ of MM in the 
specified patient group captures all of the important factors related to the natural history of 
the condition. However, as above, the model may not capture important issues such as the 
relevance of ‘time to relapse’ (e.g. 1-month treated the same as 10-months to relapse), or 
the importance of the adverse events profiles. 
 
The economic evaluation assumes that costs for ‘other resource use’, as estimated in the 
study by Bruce et al (1999),12 (non bortezomib/HDD costs) are evenly spread over time.  The 
ERG considers this to be a pragmatic assumption given the limited evidence presented in 
the manufacturer’s submission on resource use and costs for ‘other’ resources.  Whilst 
Appendix 10 of the manufacturer’s submission indicates a literature search has been 
undertaken to identify UK cost studies no comment or detail is provided on such a literature 
search in the submission. 
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The model uses data from the study by Kumar et al (2004)11  (Mayo clinic data, Rochester 
USA), to predict the baseline disease progression for the comparator group, i.e. HDD treated 
patients.  This assumes that the data from Kumar et al11 are able to reflect disease 
progression in the specified patients (controls).  Whilst the Kumar et al study seems a good 
quality observational study, and there is an absence of alternative data sources available 
(see below), when applying this data in the context of the CEA presented there may be 
some areas of uncertainty.  For example, the patients used from the Kumar et al11 study are 
(i) a subset of the Mayo patient data presented, (ii) this observational study reports data 
collected over a 13-year period (in a USA context), and patients may not have benefited 
from the latest treatment protocols, (iii) HDD was not one of the reported treatment regimens 
for the observational study, (iv) the observational data are not specific on which patients had 
what treatment and when, (v) that there are some differences in the APEX RCT and Mayo 
patient profiles, e.g. patients in APEX RCT are diagnosed approximately 5 years earlier than 
the Mayo patients.  The Mayo study data show 355 persons receiving a 2nd regimen, the 
biggest group (n=160) getting combination alkylating agents, with 33 patients received VAD 
(where dexamethasone is expected to be the most active ingredient).  In the dataset 
presented by Kumar et al11 114 persons received VAD as 1st regimen.  The suitability of this 
data is open to some judgement and interpretation.  The manufacturer’s submission 
indicates a literature search was undertaken to identify epidemiological data to model longer-
term survival for both bortezomib and HDD patients (Appendix 10), but the study by Kumar 
et al, Mayo Study, was the only one identified.  The manufacturer’s submission does not 
discuss any alternative data sources.   
 
The ERG suggest that the data used may predict a more severe disease progression/profile 
(e.g. time to progression may be shorter than expected, and mortality may be higher) than 
may be expected in a hypothetical cohort of patients treated with HDD in a RCT context (i.e. 
a direct comparison to the data applied for bortezomib from the APEX RCT).  This 
suggestion is based on the issues discussed above.  These issues could bias the estimates 
of treatment effect, given the model uses transit probabilities for the base case and adjusts 
these for treatment effect using hazard rates from the APEX RCT data.  The submission 
does make an adjustment to the observational data to reflect the survival rate of HDD 
patients calculated from the APEX RCT (patients who had received only one prior therapy 
and then received HDD).  The impact of alternative estimates for the transit probabilities 
used is uncertain, and it has not been addressed as part of the sensitivity/scenario analyses 
reported.   
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The submitted model assumes that patients may switch to more than one regimen when in 
later cycles of a 1-year duration.  For example patients may progress from regimen 2 to 
regimen 6 in the course of one (1-year) time-cycle. The model also assumes that patients 
may die in any of these cycles (p240). There may be an overestimation of the death rates 
but it is not clear what effect this has on results. The validation of the model outcomes is 
discussed in more detail below. A shorter cycle length may overcome/weaken these 
assumptions. 
 
The model assumes that there is an overall survival hazard ratio of 0.42 (from APEX RCT) in 
the first year and 0.83 in years 2 and 3. The latter hazard ratio has not been justified. 
 
The manufacturer’s submission assumes that there are independent benefits for TTP and 
OS. Given the workings of the model these benefits may not be independent, and it may be 
that the group of patients who have OS benefits will also have TTP benefits. Thus there may 
be some double counting for the effect of bortezomib.  The submission states this not to be 
the case, but the ERG would like further clarification on this.   
  
6.3.4 Data Inputs 
6.3.4.1 Patient Group 
The analysis uses MM patients who have experienced a first relapse of treatment for MM.  
The model does not have patient characteristics as specific model/data inputs.  The primary 
CEA uses a patient group with only one prior treatment (at first relapse) i.e. a subgroup of 
the APEX trial (approx. 40% of patients).  Scenario analyses are presented for a patient 
group consistent with the APEX trial participants where the inclusion criteria is for at least 
one relapse (in APEX 60% of patients started the trial at second relapse and beyond).  The 
APEX trial data is from patients with a median age of 61-62 years, with median time from 
diagnosis between 3.1 and 3.5 years. 
 
UK practice up to now would seem to be that bortezomib has been used in patients after 
second relapse, and whilst it is likely to be more readily used in earlier stages of disease 
(after first relapse) where recommended by NICE, it may still be used in a broader patient 
group than those with only one relapse.  The cost effectiveness of treatment differs quite 
widely between the specified patient groups. 
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6.3.4.2 Clinical Effectiveness 
Treatment effect is modelled over time.  It is based on hazard ratios reported in the APEX 
RCT for (a) time to progression and (b) overall survival, with the effect from treatment 
modelled on the basis of an adjustment (via hazard ratios) to a baseline prediction of 
treatment pathway and disease progression.  Actual treatment effect, i.e. the difference in 
the numbers of patients in the treatment and control group, is relative to the underlying 
transit probabilities used to model baseline treatment and progression.  The earlier sections 
of the current report have presented a review of the APEX RCT.  An equally important 
aspect of the CEA/model is the baseline cohort predictions.  The baseline cohort are 
modelled on the basis of data from an observational study in MM patients at the Mayo clinic 
(USA), (Kumar et al 200411).  Whilst the approach taken appears reasonable to the ERG, the 
submission does not discuss quality assessment / limitations in the data used for the HDD 
group. 
 
In the model the treatment effect is assumed to last for three years in the model, and the 
ERG consider that this has not been justified sufficiently in the report. 
 
One observation of the ERG is that the modelling undertaken has used the rates seen in the 
Mayo clinic study without aggregating data from different groups. Hence there may be 
concern that for some transition rates (probabilities) the small numbers in the subgroups  
(see Table 7 of ERG report) have led to unrealistic transition rates for the 5th and 6th 
regimens. A more appropriate approach may have been to aggregate these subgroups. 
Note:  See Addendum to this ERG Report, where the manufacturer provides additional 
information on this point. 
 
 
6.3.4.3 Patient outcomes 
Trial outcomes of time to disease progression, and overall survival have been used in the 
CEA.  No patient related measures of HRQL have been discussed, or applied.  Note:  See 
Addendum to this ERG Report, where the manufacturer provides additional information 
including discussion of QALYs.  The submission refers to the collection of EQ-5D data as 
part of the APEX RCT but no data are presented on this outcome.  The submission refers to 
data collected in the APEX RCT on the EORTC-QLQ30 but data for the individual 
dimensions of this health status instrument have not been presented in the submission (or in 
the published study). 
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As above (5.1.3) the submission presents an argument for not using the EQ-5D in this 
patient group, however, this argument is not generalisable to use of HRQL per se, especially 
as the submission itself highlights the negative impact of MM on the quality-of-life of this 
patient group. Although the ERG have not undertaken systematic reviews in this area we 
have identified a number of studies that have reported health state values for the MM patient 
group.  Gulbrandsen et al (2001)16 use EORTC-QLQ30 data from trial participants and ‘map’ 
to provide a single index utility score (using the 15-D generic health state classification 
system).  They present estimated societal preferences from this mapping process (map to 
15-D general population values), from the EORTC-QLQ30 health state descriptions (which 
they admit involves some subjective judgement and uncertainty), with a value of 0.7334 
estimated at 6-months in the treatment arm (high dose melphalan) of the trial data used,  
and 0.7896 in the control group (MP).  Further detail is provided on HRQL domains and the 
QLQ30 scores by the Gulbrandsen et al (2001), (see original study for further detail).  
 
Van Agthoven et al (2004)17 report an estimated health state value for MM at 0.644 for 
patients with a mean age of 54-years with previously untreated MM, stage II or III A/B 
disease.  The authors used an age-specific EQ-5D weight (0.8), and adjusted this by -19.5% 
to correct for MM.  This analysis was reported in the context of a RCT (the HOVON 24 
Study).18  The health state value is stated to be for patients who “were in an undefined state 
following intentionally curative primary therapy” (van Agthoven et al, p1162). 
 
The above studies indicate a health state value between 0.644 and 0.789 may be 
appropriate for patient groups with MM.  However, Kind et al (1998)19 have reported health 
state values in the UK general population by age group, valued using the EQ-5D, with those 
aged between 60-69 years ranging between 0.829-0.806.  Therefore health state values for 
those with MM may be expected to be somewhat lower.  The use of a health state value of 
0.80 (simply applied to the estimated survival difference) in patients treated with 
bortezomib/HDD, would lead to an estimated cost per QALY of £38,374 in the primary cost 
effectiveness analysis presented (compared to £30,750 per LYG presented in the 
submission).   
 
Health state values could be simply incorporated into the model. This could be done by 
assuming a constant health state value for all patients in all different regimens or by varying 
health state values for different regimens.  Note:  See Addendum to this ERG Report, where 
the manufacturer provides additional information on this point. 
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6.3.4.4 Resource use 
Treatment cost is calculated from therapy given (doses administered) in the APEX trial, and 
UK unit cost data from the British National Formulary (no. 48).20   The submission reports a 
calculation of doses across a range of patients (responders, non-responders, progressive 
disease) to estimate an ‘all patients’ ITT cost for both bortezomib and HDD therapy.  The 
estimated mean cost per patient for bortezomib in the model is £21,035 (based on an 
estimate mean of 25 doses of bortezomib per patient), and for HDD it is £82.  These data 
differ slightly from those presented in Appendix 14 of the submission.  The estimated mean 
cost for bortezomib therapy for responders is circa. £27,000 per patient (based on a mean 
33 doses of bortezomib) in the ‘ITT’ cost calculation.   
 
The ERG consider the estimate of cost for bortezomib to be a reasonable estimate. Each 
treatment cycle comprises bortezomib therapy at 1.3mg/m2, with 4 doses per cycle.  Each 
vial is 3.5mg and the price excluding VAT is £762.38, giving a bortezomib cost of £3,050 per 
cycle, assuming 1 vial per dose.  Therefore a patient receiving 6 cycles of treatment will 
have a bortezomib cost of £18,297, plus an additional administration cost per dose.   
 
The manufacturer’s submission estimates an administration cost per dose of £79, with a 
mean total administration cost of £1,672 per patient.  The ERG considers this may be an 
underestimate of the actual resource use and cost for the administration of each dose of 
bortezomib.  Assuming treatment via an outpatient clinic, each dose will involve an 
outpatient visit (estimated at between £86 and £93 each, for clinical haematology or clinical 
oncology, NHS Reference Costs21), plus additional pharmacy preparation time (estimated at 
£20-£25 each dose, from clinical advisors).  Therefore the administration cost per dose may 
be in excess of £100, with a total mean administration cost per patient in excess of £2,500. 
 
Of note is the issue of waste in the dosing / administration of bortezomib.  Given that the 
average person’s body surface area is much less than 2.7m2 (the surface area relevant for a 
3.5mg vial), the packaging for bortezomib leads to significant waste where one single vial is 
used per dose.  In the Phase II RCT22 for bortezomib the mean patient body surface was 
1.98m2 (Richardson et al 2003).  With the assumption of a single use per vial there will be 
waste in the provision of bortezomib therapy.  The ERG estimates that almost 1mg per vial 
will be wasted, where patients have a surface area of 1.98m2.  The ERG estimates that 
where patients can be treated in a group / cohort (i.e. in scheduled clinic approach) there 
may be cost savings where the product can be used without waste.  This saving could be as 
much as £5,000 per patient over a course of 6 treatment cycles (24 doses), assuming 
1.98m2 surface area and no waste.  Assuming that 0.5mg of a 3.5mg vial is wasted (unused) 
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the estimated cost saving is circa. £2,350 per patient (over 24 doses).  These estimated cost 
savings where the assumption of ‘single use’ per vial is dropped are illustrative, and it is not 
known how feasible it is in practice to deliver such savings in a hospital clinic or inpatient 
setting.  The manufacturer’s submission does not discuss/refer to these potential cost 
savings. 
 
The manufacturer’s submission does not discuss any systematic methods used to search for 
and identify data on resource use.  Although Appendix 10 does indicate that a systematic 
search was undertaken to identify UK studies on resource use/cost for MM.  The submission 
uses data from one published study (Bruce et al 1999)12 to inform on resource use, and unit 
costs associated with, “other” cost items i.e. costs other than the intervention cost.  This 
study is based on expert opinion, with the experts drawing on experiences generally and 
from involvement in the MRC VI Myelomatosis trial.13)  The MRC VI Myelomatosis trial 
included patients at diagnosis of MM treated with initial chemotherapy (using non-stem-cell-
directed therapy) i.e. patient group differed from that used in the APEX RCT and the 
economic analysis presented in the manufacturers submission.   That the study data are 
based predominantly on expert opinion is not discussed clearly in the submission.  Quality 
assessment / limitations in the data used are not discussed.   
 
The data from the cited study were in 1997 UK pounds, and the methods used in the 
submission to up-rate these costs were incorrect (from the Excel model, the submission 
used 1999 as a base year, and did not apply accepted cost/year indices).  Where the 1997 
estimate of cost per month is taken from the Bruce et al study12 and up-rated to 2004/5 costs 
(latest available via PSSRU report23) using HCHS indices (173.5 for 1997/8, 234.2 for 
2004/05),23 the ERG estimate a cost per month of £470 (as opposed to £443 in the 
manufacturer’s submission).  This issue does not have a substantive impact on the cost 
effectiveness estimates presented.  Note:  See Addendum to this ERG Report, where the 
manufacturer provides additional information on this point. 
 
The manufacturer’s submission does not address the issue of additional resource use 
attributable to adverse events which may be more frequent with the use of bortezomib, 
compared to HDD.  The clinical evidence has indicated that there are a greater number of 
adverse events in the bortezomib group than the HDD group (APEX RCT4).  The economic 
evaluation presented only allows for some additional treatment costs associated with 
bortezomib in a sensitivity analysis (increasing the monthly cost for ‘other costs’ by 25% in 
the bortezomib patient group i.e. from £443 per month to £554 per month).  This sensitivity 
analysis, based on an extra £1,329 per year per patient leads to an increase of £2,646 in the 
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cost per life-year-gained (from £30,750 to £33,406 per life-year-gained).  In practice patients 
may be prescribed bisophosphates to prevent/treat adverse events, with an annual cost of 
approx. £360 (estimate of £30 per month from clinical advisor).  Where serious adverse 
events occur (e.g. thrombocytopenia, peripheral neuropathy) they may involve significant 
resource use / cost for treatment of the events themselves and their consequences.  This 
issue has not been discussed in the manufacturer’s analysis. 
 
6.3.4.5 Costs 
As above, unit cost data for bortezomib and HDD are from the UK BNF (no. 48).  The cost 
used for bortezomib is still current at March 2006.  Other cost data are used directly from 
one published study (Bruce et al 1999)12.  Cost data are presented in the submission as 
2005/6 UK pounds (see comments above).  Costs associated with adverse events, and 
treatment to prevent adverse events, have not been discussed. 
 
6.4 Consistency 
The ERG has examined the submitted Excel model for internal and external consistency and 
accuracy. This was made more difficult by a lack of documentation on how the model works, 
and the ERG provide a brief overview in this section. 
6.4.1 Internal consistency 
Random checking has been done for some of the key equations of the model, for example 
on Excel worksheets titled Vprobs, Velcade only and V mn 1-3, Vmn 4-6.  The ERG has not 
undertaken a comprehensive ‘checking’ process against all cells in the model. The model is 
fully executable and inputs changed in the Summary sheet (cells D4:F25) produce 
immediate changes to the deterministic results in this sheet (cells J5:N17). These parameter 
inputs and model outcomes are shown in Table 28 and Table 31 respectively of the 
manufacturer’s submission. The ‘Summary’ worksheet in the Excel model is clear and user 
friendly. The model is shown using the baseline scenarios described and the user is able to 
choose the other scenarios described in the submission (on pages 85-88) by clicking on a 
drop down menu/button (worksheet cell H20). 
 
Excel worksheets titled Mayo and Dex show the transition parameters/probabilities used 
from the Mayo observational study which are used for the baseline worksheet, Dex. These 
data are shown in Table 7 below. The transition probabilities used are taken directly from 
these data although they have been adjusted by calibration to the APEX trial (see 
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submission, p242). Furthermore the timing of cycle lengths in the model correspond with the 
data presented in this Table. The data shown in the Table correspond to the percentages of 
patients who die, switch to another regimen or remain on that regimen by the end of 
specified time periods. As mentioned above there are concerns that the direct use of these 
data leads to unrealistic transition rates in some regimens and time cycles and that the cycle 
length used is too long. 
 
 
Table 7 Patient experience with each regimen* 
 
 
Excel worksheets Dex and Velcade show the transition probabilities. The proportion of 
people in each of the regimens over time is shown in the worksheets D probs, V probs and D 
+ V probs for each of the comparators. The model has incident cohorts who start in each 
regimen in each cycle. These values are worked out by matrix multiplication using values 
from the worksheets titled in the format V Mn 1-3, which themselves are from the input 
parameters shown in the related worksheets, e.g. Velcade only. The transition probabilities 
are defined according to the time that a patient has spent in a regimen so the model is 
subdivided into the time each of the cohorts have been in this regimen. The effect of this 
approach is a cumbersome and difficult to interpret series of spreadsheets. 
 
 
The ERG has discovered several potential errors: 
• The model uses a survival benefit for other regimens when the patients are not 
treated with Bortezomib, ie regimens 3-6, see sheet Velcade only.  
Note:  See Addendum to this ERG Report, where the manufacturer provides additional 
information on this point. 
 
• There seem to be mistakes on some of the sheets with the transition probabilities. 
For example, cell AP43 on the V mn 1-3 sheet uses HDD probabilities rather than 
Source: Kumar et al11. Mayo Clin Proc 2004. 
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velcade probabilities (='Dex only'!$Q$15). This occurs countless times on this sheet 
and the other transition probability sheets. 
Note:  See Addendum to this ERG Report, where the manufacturer provides additional 
information on this point. 
 
• There may be a problem with double counting. The group who are saved from dying 
may also have a longer time to disease progression. 
  
However, notwithstanding the comments above, the ERG view the model as a reasonable 
approach to predicting treatment profiles in this patient.  From the random checking 
undertaken the ‘wiring’ of the model appears accurate, with the exception of the points 
raised above.  Parameter inputs were checked for correct predictive validity i.e. ERG 
undertook some independent sensitivity analyses and results were consistent with those 
expected (results were in the right direction). 
 
6.4.2 External consistency 
The model used the Mayo observational study data and was validated against this data for 
overall mortality (submission, p241). The authors of the manufacturer’s submission claim 
that the model has survival of 72% at 1-year, 61% at 2-years and 25% at 5-years compared 
to Mayo study findings of 72% at 1-year, 55% at 2-years and 22 % at 5-years.  However the 
ERG were not able to replicate these results.  Note: See Addendum to this ERG Report, 
where the manufacturer provides additional information on this point. 
 Where the ERG has explored the model, excluding the adjustment of a reduced mortality 
risk in the first year of 21% (see below), the ERG found the results in the model to be 64% at 
1-year, 39% at 2-years and 10% at 5-years. It may be that the model uses different 
parameter values, for example for the hazard ratios, but this has not been made clear. 
 
The manufacturer’s submission states that the model has been calibrated against the trial 
arm of the APEX trial (submission, p242) by reducing the mortality risk while on a 2nd 
regimen in the first year by 21%.  The ERG were unable to replicate these results. Note:  
See Addendum to this ERG Report, where the manufacturer provides additional information 
on this point.  The model shows 87% and 72% 1-year survival for bortezomib and HDD, 
compared to 80% and 66% as reported in the published APEX RCT findings (Richardson et 
al).4  
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Figure 1 Patient survival for HDD and bortezomib for the APEX trial and model results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The ERG has compared model results to the Kaplan Meier Survival Curve presented in the 
manufacturer’s submission (p49, Figure 10). The Figure 10 presented in the manufacturer’s 
submission is for all patients in the APEX trial, rather than only those after first relapse (OS 
RR = 0.57).  Therefore the ERG has compared results from the model scenario using the all 
APEX patient group.  The ERG has used hazard ratios of 0.95 and 1 in the worksheet 
(worksheet cell reference F85 and E85), rather than 1 and 0.79 respectively in the 
manufacturer’s submission analysis.   This was done to calibrate the model for first year 
survival against the APEX trial.  The ERG Figure 1 above shows that using these hazard 
ratios, the model shows good agreement with the control arm of the trial and for the 
treatment arm for the first year. But, after the first year, the model overestimates patient 
survival in the treatment arm. Furthermore the treatment effect is also higher than shown in 
the trial by roughly 40% over the two years. The ERG considers that the model may 
overestimate the treatment effect of bortezomib. 
 
 
6.5 Assessment of Uncertainty 
6.5.1 One-way sensitivity analyses 
The manufacturer’s report presents sensitivity analyses on the key parameters in the model 
(Table 8). It presents the influence of the parameters in a Tornado diagram (Figure 37, p89). 
According to results presented, the most influential variable is the duration of the treatment 
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effect. The sensitivity analyses can be changed in the Excel model on the Sens sheet and 
produces results in the Figures worksheet. Sensitivity analysis inputs can be changed easily 
and the results are updated quickly. The ranges chosen for the sensitivity analyses are not 
representative of the variability of the data. For example the 95% confidence interval for the 
TTP hazard ratio was 0.44-0.69 (p48) whereas the range used in the report was 0.51-0.61.  
In general the ERG consider the parameter ranges used were not wide enough. 
 
Table 8 One way sensitivity analyses (from manufacturer’s submission, p.88) 
    Inputs CE ratios 
Variable Basecase Left Right Left Right 
Range
Duration of treatment effect, 
years 
3 4 2 £27,957 £36,747 £8,790
Hazard ratio - TTP 0.56 0.51 0.61 £28,465 £33,605 £5,141
Cost of other care - Bortezomib 
pre-progression 
£443 £443 £554 £30,760 £33,407 £2,646
Cost of Bortezomib per course £21,035 £20,033 £22,086 £29,534 £32,027 £2,493
Cost of other care - pre- and 
post-progression 
£443 £354 £554 £29,431 £31,804 £2,374
Hazard ratio - OS 0.42 0.38 0.47 £30,200 £31,389 £1,189
Cost of HDD per course £82 £86 £78 £30,745 £30,755 £9
 
Note:  See Addendum to this ERG Report, where the manufacturer provides additional 
information on this point. 
 
Further sensitivity analysis has been undertaken by the ERG, see below.  
 
6.5.2 ERG sensitivity analysis 
More appropriate ranges have been used for the one way sensitivity analysis. The ERG has 
used the 95% confidence intervals for the hazard ratios and have estimated a range of +/- 
25% for the costs. A cost of £470 has been used for the other care costs not including 
bortezomib. The amended one-way sensitivity analyses are shown in Table 9. According to 
these analyses, the most influential variables were the TTP hazard ratio and the cost of 
bortezomib.  
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Table 9 Amended one way sensitivity analyses 
    Inputs CE ratios 
Variable Basecase Left Right Left Right 
Range 
Hazard ratio - TTP 0.56 0.44 0.69 £25,339 £39,141 £13,802
Cost of Bortezomib per course £21,035 £15,776 £26,294 £24,365 £37,136 £12,770
Duration of treatment effect, 
years 
3 4 2 £27,957 £36,747 £8,790
Cost of other care - Bortezomib 
pre-progression 
£470 £352 £588 £28,266 £33,892 £5,627
Hazard ratio – OS (year 1) 0.42 0.30 0.60 £29,317 £33,175 £3,858
Cost of other care - pre- and 
post-progression 
£470 £352 £588 £29,682 £32,476 £2,795
Cost of HDD per course £82 £103 £62 £30,725 £30,774 £50
 
The sensitivity analysis only considers OS hazard ratio for the first year. A sensitivity 
analysis was run for the OS hazard ratio for year 2 and 3 using an estimate of its 95% 
confidence intervals. The cost effectiveness ratios ranged from £28,782 to £32,202. A 
sensitivity analysis was run where each of the hazard ratios (TTP and OS) were varied in the 
same direction at the same time (low and high scenarios) and the cost effectiveness ratios 
ranged from £23,287 - £46,814. A sensitivity analysis where the cost of bortezomib varies by 
+/- 50% gave cost effectiveness ratio from £18,311 - £43,850. 
 
 
6.5.3 Scenario Analysis 
 
Following discussion of the base case scenario, three further scenarios analyses are 
presented in the manufacturer’s submission:  
 
(i) Limiting the number of cycles of treatment in non-responding patients 
The number of cycles is reduced from 8 cycles to 3 cycles for non-responding patients. 
However, almost 15% of patients achieved a response in the trials after 3 cycles and these 
would have their treatment stopped. They assume that overall survival falls from 11.2 
months to 9.4 months and the cost of treatment drops by £5,427. The ICER falls to £27,926 
per life-year-gained. 
From discussion with clinicians the ERG understands that this scenario is reflective of UK 
current practice. 
 
(ii) Using the overall population of the APEX Trial 
In this scenario, 40% of patients started at first relapse with the remaining 60% at second 
relapse and beyond. It is also possible in the model to start with any desired mix of patients. 
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For patients in second relapse and beyond there is a lesser benefit from bortezomib 
treatment. In this scenario the cost per life year gained increases to £39,954. However, this 
scenario uses a hazard ratio of 0.43 for the 2nd and 3rd years of treatment for overall survival 
(in comparison to 0.83 in the baseline scenario). If a hazard ratio of 0.83 is used in the later 
years, as in the base case scenario, the ICER increases to over £46,000 per life-year-
gained. 
 
Treating patients with bortezomib earlier in the treatment pathway is shown to be more cost-
effective compared to later intervention. Where patients are treated at a later stage the cost 
per life-year-gained increases significantly.  For example, where the ERG has run analyses 
for a scenario where all patients are treated after their second relapse the ICER is over 
£77,000 per life-year-gained, with an ICER of £107,000 where all patients are treated after 
the third relapse. This finding may be in conflict with a situation where service provision is 
considered in the context of budget impact (i.e. providers only being able to treat a certain 
number of patients, and therefore waiting until later in the treatment pathway), such as may 
have been the case in current practice with bortezomib used as third-line therapy. 
 
From discussions with clinical advisors the ERG understands that current practice has been 
to use bortezomib for third line treatment.  Should NICE recommend bortezomib for the 
treatment of patients with MM in line with the licence indication it may be that bortezomib is 
used across a patient group that varies by staging of disease/treatment (e.g. 1st 2nd, 3rd, 4th 
relapse), and the cost effectiveness considerations of this will be important. 
(iii) Bortezomib and HDD combination therapy Vs HDD only 
The scenario presented in the submission using a combination of HDD and bortezomib 
assumes that the response rate is increased by a factor of 1.24. The manufacturer’s 
submission makes several assumptions in estimating the new parameters for the model and 
these are unclear (Appendix 15). This scenario analysis produces a cost per life-year-gained 
of £28,281. 
 
The Excel spreadsheets Velcade + Dex and Velcade used different methodology to 
calculate transition probabilities after one year, e.g. cell S57. In particular, patients switch to 
other treatments regimens in Velcade but do not in Velcade + Dex.  
 
From discussions with clinical advisors the ERG believe that the combination of bortezomib 
and HDD is likely to be the treatment option used in practice. 
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Further scenario analyses have been undertaken by the ERG, see below. 
6.5.4 ERG scenario analysis 
From discussions with clinical advisors the ERG considered that a combination of the three 
scenarios is likely to be used in practice. The ERG considered an analysis with bortezomib 
and HDD combination therapy vs HDD across a patient group that varies by staging of 
disease and treatment where the number of cycles of treatment is limited in non-responding 
patients. Table 10 shows the estimated cost effectiveness ratios with different patient 
groups. 
Table 10 Cost effectiveness results for additional scenario analysis (combining scenarios 1-3) 
Patient group* Cost per life-
year-gained 
All patients treated at 1st relapse £27,334 
80% patients treated at 1st , 20% at 2nd relapse £30,219 
60% patients treated at 1st , 30% at 2nd , 10% at 3rd relapse  £35,783 
40% patients treated at 1st , 40% at 2nd , 20% at 3rd relapse £44,602 
*Note: Intervention is bortezomib plus HDD vs. HDD alone; the number of cycles of treatment is 
limited in non-responding patients; mix of patients by stage of treatment. 
 
6.5.5 Probabilistic Sensitivity Analysis 
The manufacturer’s model has a probabilistic sensitivity analysis (PSA) on the Sim 
parameter Excel worksheet. The PSA can be run by clicking on the ‘Velcade vs HDD button’ 
and takes about 3 minutes to run (on a computer with 2.8 GHz processor). Results are 
updated on the ‘V v D - Sim Results’ sheet.  The PSA is based around 300 simulations. 
 
The results of the PSA are presented as an acceptability curve and a scatter-plot (cost-
effectiveness plane) of the cost effectiveness results (submission, p89-90, Figures 16a & 
17a). The submission reports results from PSA (for base case scenario) between £28,855 
and £38,654 per life-year-gained for the 5th and 95th percentile.  The manufacturer’s 
submission provides the following information (in the Excel worksheet only) on the 
assumptions for selection of parameter values: 
 
Summary of assumptions for manufacturer’s PSA: 
1.  Hazard ratios and costs assumed to be distributed lognormal. 
2.  Duration of treatment effect set to probability of 35% for 2 years, 50% for 3 years, and 
15% for 4 years. 
3.  Standard deviation of the lognormal distributions of OS and TTP hazard ratio were set so 
that 95th percentile equalled +0.05 from their baseline mean values.   
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4.  Standard deviation of the lognormal distribution of costs of other care based on Bruce el 
al.12  
5.  Range of costs of bortezomib and HDD varied by +/- 5%.  
6.  The PSA did not vary policy variables (discount rate, time horizon, unit cost of 
bortezomib), but did vary random variables.  
7. Assumed that hazard ratios on TTP and OS are correlated (70%); based on expert 
opinion. 
 
Similar to the one way sensitivity analysis, the ERG considers the ranges used for the PSA 
to be inappropriate (e.g. where possible ranges should be related to the confidence intervals 
of the data). In general the ranges used should be wider. The distributions used (e.g. 
lognormal distribution for hazard ratios) are generally appropriate for these data, as there are 
no hard and fast rules.  However it is common practice for the Gamma distribution to be 
used for cost data parameter inputs (where a lognormal distribution is used in the 
submission).  
 
The ERG has undertaken further probabilistic sensitivity analysis, see below.  
 
6.5.5.1 ERG probabilistic sensitivity analysis 
The ERG has used the 95% confidence intervals for the hazard ratios and has estimated a 
range of +/- 25% for the costs. A cost of £470 has been used for the ‘other care costs’. The 
baseline scenario is shown in Figure 2 and Figure 3 with more appropriate ranges for the 
probabilistic sensitivity analysis. The result of the probabilistic sensitivity analysis shows that 
the 5th percentile is £22,693 and the 95 percentile is £46,751 (cost per life-year-gained). A 
probabilistic sensitivity analysis where the cost of bortezomib varies by +/- 50% had a 5th 
percentile of £20,364 and 95th percentile of £49,876. 
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Figure 2.  Cost-effectiveness acceptability curve from ERG Probabilistic sensitivity 
analyses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Cost Effectiveness Plane 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.6 Comment on validity of results presented with reference to 
methodology used 
 
In general the approach taken to model disease progression and cost effectiveness in this 
patient group seems reasonable.  A number of concerns have been raised above by the 
ERG, some general and some specific.  The ERG has not undertaken systematic searches 
in this area therefore the comments made are for broader consideration by the NICE 
Appraisal Committee in the context of this STA. 
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6.7 Summary of uncertainties and issues 
 
In general the approach taken to model disease progression and cost effectiveness in this 
patient group seems reasonable.  A number of concerns have been raised above by the 
ERG, some general and some specific: 
 
− The manufacturer’s submission uses data from the APEX RCT and Mayo observational 
study.11 The ERG has concerns on the generalisability of these data to UK treatment 
practice.  
 
− No patient related measures of health-related quality-of-life have been discussed or 
applied in the manufacturer’s submission and the model outcomes are reported in terms 
of cost per life-year-gained.  Mulitple myeloma patients generally have a relatively poor 
quality of life (compared to age matched controls) and the ERG suggest that this should 
be incorporated in the manufacturer’s model.  Note:  See Addendum to this ERG Report, 
where the manufacturer provides additional information on this point. 
 
− The ERG has identified several mistakes in the Excel spreadsheet submitted. 
Furthermore the results from the model may overestimate the treatment effect shown in 
the APEX trial.  Note:  See Addendum to this ERG Report, where the manufacturer 
provides additional information on this point. 
 
− Treatment cost is a key issue in the cost effectiveness estimates, and the ERG note that 
(i) the cost for bortezomib will vary by responder status (number of cycles), (ii) cost 
savings may be possible where group administration of bortezomib is an option. 
 
− The sensitivity analyses undertaken are limited, and there may be a greater variability in 
the cost effectiveness of treatment than presented in the manufacturer’s submission 
 
− Adverse events have not been included in the manufacturer’s model, either in terms of 
loss of quality of life or increased resource use. 
 
In view of the points raised above, the ERG suggest that the cost effectiveness results 
presented may underestimate the cost per life-year-gained for bortezomib therapy (vs. 
HDD), where potential UK practice and scenarios are considered.   
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7 Discussion  
 
7.1 Summary of clinical effectiveness issues 
The manufacturer’s submission to NICE includes a systematic review of the clinical 
effectiveness literature and narrative reporting of the RCT that met the inclusion criteria of 
the review (APEX trial).   
 
The ERG has two main areas of concern relating to clinical effectiveness issues in the 
manufacturer’s submission; firstly, the limited evidence base and its relevance to the NHS, 
and secondly, the interpretation of the included RCT. Whilst the submitted evidence 
generally reflects the decision problem as defined in the manufacturer’s submission, it is not 
totally representative of current clinical practice in the UK in either the use of bortezomib or 
the comparator. Due to the nature of the disease and patient population no standard 
treatment exists for MM patients at first relapse and beyond, which makes comparisons 
difficult and limits available evidence. The submitted evidence consists of the only published 
RCT concerning bortezomib and as such may be helpful for answering some questions 
concerning myeloma treatment that will impact on the NHS. 
 
The manufacturer’s submission states that bortezomib increases survival and time to 
disease progression compared with HDD.  Although this conclusion is probably valid, the 
size of the treatment effect of bortezomib is not known. There is uncertainty about the results 
and the statistical methods used in the analysis because of lack of details and clarity in 
reporting patient numbers and the intervention they received at any time, and because point 
estimates and confidence intervals are not presented consistently.    
 
7.2 Summary of cost effectiveness issues 
The manufacturer’s submission to NICE includes a report on the cost effectiveness 
literature, reference to an early economic analysis undertaken using individual patient-level 
trial data and an economic evaluation using a decision-analytic model. 
 
The state transition model predicts treatment experience, modelling the flow of patients 
through a series of treatment regimens. The clinical effectiveness data from the APEX RCT, 
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showing relative benefits in time to treatment progression and overall survival, are applied to 
the baseline prediction for HDD patients to simulate the treatment effect from bortezomib.  
 
In general the approach taken to model disease progression and cost effectiveness in this 
patient group seems reasonable.  A number of concerns have been raised above by the 
ERG, some general and some specific. The ERG has concerns on the generalisability of the 
data used to UK treatment practice. No patient related measures of health-related quality-of-
life have been discussed or applied in the manufacturer’s submission and the model 
outcomes are reported in terms of cost per life-year-gained.  Note:  See Addendum to this 
ERG Report, where the manufacturer provides additional information on this point.  The 
ERG has identified several mistakes in the Excel spreadsheet submitted. Note:  See 
Addendum to this ERG Report, where the manufacturer provides additional information on 
this point.   Furthermore the results from the model may overestimate the treatment effect 
shown in the APEX trial. Treatment cost is a key issue in the cost effectiveness estimates 
and the cost for bortezomib will vary by responder status and method of administration. The 
sensitivity analyses undertaken are limited, and there may be a greater variability in the cost 
effectiveness of treatment than presented in the manufacturer’s submission. Adverse events 
have not been included in the manufacturer’s model, either in terms of loss of quality of life 
or increased resource use. 
 
In view of the points raised above, the ERG suggest that the cost effectiveness results 
presented may underestimated the cost per life-year-gained for treatment with bortezomib 
compared to HDD, where potential UK practice and scenarios are considered. 
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Addendum: Manufacturer’s response to questions raised 
by the ERG on the manufacturer’s submission to NICE   
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